dpp 4 inhibitor and glp 1 receptor agonist combination Frontiers Dipeptidyl Peptidase-4 Inhibitors: A Systematic
Description
What this study adds: We also confirm cognitive deficits in IIH patients with raised ICP notably in executive function
Drugs with indication and recent clinical evidence The pathophysiology of MASLD and MASH integrates insulin resistance, lipotoxicity, inflammation, and fibrogenic remodeling
These include liraglutide (Saxenda) and semaglutide (Wegovy), representing an expansion beyond their original diabetes indication and highlighting the broader metabolic impact of GLP-1 pathway activation
The GLP-1 RA are still under prescribed in developed and well-funded health care systems and are not even available in the most modern formulations in some parts of the world
Aguiar AF, Janurio RS, Junior RP, Gerage AM, Pina FL, do Nascimento MA, et al
